Case report raises caution on dapagliflozin for canine CaOx stones

A newly published case report details an off-label trial of dapagliflozin in a dog with recurrent calcium oxalate urolithiasis, offering an early real-world look at a drug class that has attracted interest well beyond diabetes. In the reported 8-year-old Chihuahua, dapagliflozin was used after standard preventive measures had failed to stop recurrence, but the drug did not reduce urinary calcium excretion and was discontinued after 12 days because of concern for underhydration. The report lands at a time when SGLT2 inhibitors are drawing more veterinary attention for their renal and cardiometabolic effects, making even a negative single-patient experience relevant. (pmc.ncbi.nlm.nih.gov)

The clinical backdrop matters. Calcium oxalate urolithiasis remains one of the most important recurrent stone diseases in dogs, particularly in small-breed, older, and often male patients. Chihuahuas are among the breeds overrepresented for calcium oxalate stones, and recurrence is a persistent challenge because these stones generally require removal rather than dissolution. Standard prevention typically focuses on increasing water intake, feeding therapeutic diets, and in selected recurrent cases considering agents such as hydrochlorothiazide, which has evidence for reducing urinary calcium excretion in dogs. (merckvetmanual.com)

That helps explain why dapagliflozin was an intriguing, if unconventional, choice. SGLT2 inhibitors reduce renal glucose reabsorption, producing glucosuria and an osmotic diuresis. In theory, a drug that alters renal tubular handling could be worth exploring in hypercalciuric stone formers, especially given human interest in SGLT2 inhibitors and kidney stone biology. But the canine evidence base is still thin, and the available dog studies have focused more on cardiac or metabolic effects than on urolith prevention. Recent work in dogs with heart disease found short-term dapagliflozin was associated with marked glucosuria without clinically relevant hypoglycemia, reinforcing that the class has predictable renal effects in dogs even outside diabetic use. (pmc.ncbi.nlm.nih.gov)

In this case, however, the hoped-for signal did not appear. According to the report summary, dapagliflozin failed to reduce urinary calcium excretion, and clinicians stopped treatment because of concern that the dog was becoming underhydrated. That outcome is clinically important because hydration is a cornerstone of calcium oxalate prevention: if a drug increases urinary water losses without offsetting the stone-driving abnormality, it may work against one of the main therapeutic goals. The report therefore adds practical caution, not just mechanistic disappointment. (vetmed.umn.edu)

Direct expert reaction to this specific case report was limited in publicly available sources, but the broader veterinary commentary around SGLT2 inhibitors has been consistent about monitoring risk. Reviews and educational pieces on the class emphasize glucosuria, osmotic diuresis, dehydration risk, and, in some species and settings, concern for ketoacidosis. FDA communications on the feline SGLT2 drug bexagliflozin have also underscored that this class carries meaningful safety conditions, even though those warnings apply to a different species and indication. Taken together, those signals support the case report’s emphasis on close hydration surveillance when these drugs are used off-label. (vettimes.com)

Why it matters: For practicing veterinarians, this report is less about proving dapagliflozin has no role in canine stone prevention and more about sharpening the risk-benefit conversation. Recurrent calcium oxalate cases are frustrating, and the lack of medical dissolution options can make novel pharmacologic strategies appealing. But this case suggests that an SGLT2 inhibitor may introduce a management conflict: the same pharmacology that makes the drug active, namely glucosuria and osmotic diuresis, may undermine hydration goals in a patient population where urine dilution is essential. It also reinforces that off-label use of approved human drugs in animals must be handled within AMDUCA’s extralabel framework and with careful client communication about uncertainty, monitoring, and stopping rules. (pubmed.ncbi.nlm.nih.gov)

There’s also a larger research signal here. Calcium oxalate stone disease in dogs remains common and recurrent, and newer work continues to refine risk factors, biomarkers, and recurrence patterns. A negative case report won't close the door on SGLT2-based approaches, but it does raise the bar for future studies: investigators would need to show not only a favorable effect on urinary calcium or stone risk, but also that hydration status, renal parameters, and broader metabolic safety can be maintained. (pubmed.ncbi.nlm.nih.gov)

What to watch: The next meaningful step would be additional case reports or controlled pilot studies in dogs that define dosing, monitoring parameters, and patient selection, especially whether any candidate benefits on calciuresis can outweigh predictable diuretic effects over weeks to months rather than just 12 days. (pmc.ncbi.nlm.nih.gov)